

## Special Issue

# Selenium, Trace Elements and Transition Metals in Anticancer Drug Discovery

### Message from the Guest Editors

The search for new anticancer drugs and adjuvants in cancer therapy is an important challenge of the pharmaceutical sciences. Many *in vitro* and *in vivo* experimental models demonstrated the efficacy of Se compounds as anticancer agents. Selenocompounds possess the ability to interfere with the redox homeostasis and signalling of cancer cells to produce anticancer effects. Similarly, compounds and/or nanoparticles containing tellurium, cadmium, gold, rhodium and ruthenium have proven also to show anticancer effects. Taking into account their interesting activity, both selenocompounds, trace elements and transition metals are the object of intensive chemical modifications in order to find new active structures that can serve as a potential anticancer drug candidates or adjuvants in the future cancer therapy. In this Special Issue we want to present the recent advances in the drug design and potential pharmacological applications of all these elements. Articles that report the anticancer or cancer MDR reversing activity of novel compounds containing selenium, tellurium, or novel organic complexes of metals from the d-block are welcomed.

### Guest Editors

Prof. Dr. Claus Jacob

Prof. Dr. Jadwiga Handzlik

Dr. Małgorzata Anna Marć

### Deadline for manuscript submissions

closed (30 November 2022)



## Pharmaceutics

---

an Open Access Journal  
by MDPI

---

Impact Factor 5.5  
CiteScore 10.0  
Indexed in PubMed



[mdpi.com/si/73616](https://mdpi.com/si/73616)

*Pharmaceutics*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[pharmaceutics@mdpi.com](mailto:pharmaceutics@mdpi.com)

[mdpi.com/journal/  
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





# Pharmaceutics

---

an Open Access Journal  
by MDPI

---

Impact Factor 5.5  
CiteScore 10.0  
Indexed in PubMed



[mdpi.com/journal/  
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



## About the Journal

### Message from the Editor-in-Chief

*Pharmaceutics* (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

---

### Editor-in-Chief

Prof. Dr. Patrick J. Sinko  
Department of Pharmaceutics, Ernest Mario School of Pharmacy,  
Rutgers University, Piscataway, NJ 08854, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).